

NDA 050778/S-026

SUPPLEMENT APPROVAL

Pfizer, Inc. Attention: Shai Srulovich Director, Pfizer Global Regulatory Affairs 235 East 42nd Street New York, NY 10017-7555

Dear Mr. Srulovich:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 21, 2020, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ELLENCE (epirubicin hydrochloride injection).

This "Changes Being Effected in 30 Days" supplemental new drug application provides for labeling revisions to include sodium hydroxide as a pH adjuster and to include the quantity of sodium chloride.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

We note that your September 30, 2020, submission includes final printed labeling (FPL) for your prescribing information. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov NDA 050778/S-026 Page 2

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

We acknowledge your September 30, 2020, submission containing final printed carton and container labeling.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Laya Keyvan, Regulatory Business Process Manager, at (240) 402 - 4598.


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D. Branch Chief, B1 Division of Post-Marketing Activities I Office of Lifecycle Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosures:

Content of Labeling Carton and Container Labeling



Digitally signed by Ramesh Raghavachari Date: 2/18/2021 11:42:02PM GUID: 502d0913000029f375128b0de8c50020